NGNENeurogene Inc.vs its industry peers
A metric-by-metric comparison of Neurogene Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGNEThis | $695M#8 | — | 3.2x#4 | — | -100.0%#11 | -20.2%#12 | — | -41.6%#11 | — | — | 99.9%#7 | — |
| CLYM | $810M#1 | — | 3.4x#6 | — | — | 19.0%#8 | — | -25.0%#9 | — | — | 600.2%#1 | — |
| ACRS | $784M#2 | — | 6.3x#10 | 100.2x#9 | -58.2%#10 | 50.8%#6 | -975.9%#9 | -52.1%#12 | -65.8%#5 | 3#3 | 190.2%#4 | — |
| DSGN | $783M#3 | — | 3.9x#7 | — | — | -40.7%#14 | — | -34.6%#10 | — | — | 114.3%#5 | — |
| GYRE | $749M#4 | — | 6.9x#11 | 6.4x#5 | 10.2%#7 | -44.8%#15 | 9.9%#4 | 9.2%#5 | 12.0%#3 | 3#3 | -9.2%#11 | 6.0%#1 |
| COLL | $723M#5 | 17.5x#5 | 2.3x#3 | 0.9x#1 | 23.6%#6 | -8.7%#11 | 23.0%#3 | 20.2%#4 | 62.0%#1 | 4#1 | -37.7%#16 | — |
| NVCT | $712M#6 | — | 78.4x#13 | — | — | -39.2%#13 | — | -291.1%#13 | — | — | 252.4%#2 | — |
| ZVRA | $701M#7 | 12.7x#4 | 3.2x#5 | 6.6x#6 | 350.9%#2 | 178.9%#4 | -59.1%#5 | 38.2%#1 | — | — | 62.6%#9 | — |
| IRWD | $690M#9 | 5.3x#2 | — | 2.3x#3 | -15.7%#9 | 2629.5%#1 | 33.3%#2 | — | 42.6%#2 | — | 222.4%#3 | — |
| MNPR | $679M#10 | — | 5.2x#9 | — | — | 12.0%#9 | — | -10.5%#7 | — | — | 77.8%#8 | — |
| VSTM | $665M#11 | — | 13.3x#12 | 21.5x#7 | 209.1%#4 | -60.3%#16 | -550.3%#8 | -419.1%#14 | — | — | -19.5%#13 | — |
| CBIO | $637M#12 | — | 3.9x#8 | 58.7x#8 | — | 306.4%#3 | -1407.5%#10 | 0.1%#6 | — | — | 37.1%#10 | — |
| ALT | $632M#13 | — | 1.3x#2 | 15419.1x#10 | 105.0%#5 | 7.3%#10 | -230461.0%#11 | -18.6%#8 | -21.1%#4 | — | -10.7%#12 | — |
| PHAT | $622M#14 | — | — | 3.6x#4 | 216.9%#3 | 33.8%#7 | -91.4%#6 | — | — | 4#1 | -30.0%#14 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#8 | 76.2%#5 | -111.0%#7 | 22.5%#3 | — | — | 110.5%#6 | — |
| CRMD | $609M#15 | 3.6x#1 | 1.3x#1 | 2.0x#2 | 617.0%#1 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | -32.5%#15 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice